<DOC>
	<DOC>NCT01833039</DOC>
	<brief_summary>The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.</brief_summary>
	<brief_title>An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<criteria>Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or refractory disease after prior therapy are eligible. Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are not eligible. Patients previously treated with ibrutinib are not eligible. Patients enrolled in another interventional clinical study with therapeutic intent are not eligible.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Ibrutinib</keyword>
</DOC>